Quarterly report · Q1
4671.TEDINET S100OZLA
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.6bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥681m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥769m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥748m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥38.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥37.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.6bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥21.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥42.32 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.41 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥42.25 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥81.28 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 61.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥108m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥782m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥789m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥84m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥4m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 352
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ioa | Prior1YearInstant | 2641000000 | JPY |
| Other ioa | CurrentQuarterInstant | 2624000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -8000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -8000000 | JPY |
| Investments and other assets | Prior1YearInstant | 6434000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 6670000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 17588000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 17648000000 | JPY |
| Assets | Prior1YearInstant | 40256000000 | JPY |
| Assets | CurrentQuarterInstant | 38239000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 5384000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 5310000000 | JPY |
| Short term loans payable | Prior1YearInstant | 300000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 300000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 715000000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 2723000000 | JPY |
| Income taxes payable | Prior1YearInstant | 1725000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 299000000 | JPY |
| Provision cl | Prior1YearInstant | 610000000 | JPY |
| Provision cl | CurrentQuarterInstant | 196000000 | JPY |
| Other cl | Prior1YearInstant | 2652000000 | JPY |
| Other cl | CurrentQuarterInstant | 2835000000 | JPY |
| Current liabilities | Prior1YearInstant | 11389000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 11665000000 | JPY |
| Long term loans payable | Prior1YearInstant | 2340000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | - | JPY |
| Net defined benefit liability | Prior1YearInstant | 1919000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1865000000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 133000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 134000000 | JPY |
| Other ncl | Prior1YearInstant | 995000000 | JPY |
| Other ncl | CurrentQuarterInstant | 955000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 5389000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 2955000000 | JPY |
| Liabilities | Prior1YearInstant | 16778000000 | JPY |
| Liabilities | CurrentQuarterInstant | 14620000000 | JPY |
| Capital stock | Prior1YearInstant | 3371000000 | JPY |
| Capital stock | CurrentQuarterInstant | 3371000000 | JPY |
| Capital surplus | Prior1YearInstant | 3387000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 3387000000 | JPY |
| Retained earnings | Prior1YearInstant | 17479000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 17543000000 | JPY |
| Treasury stock | Prior1YearInstant | -1343000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -1319000000 | JPY |
| Shareholders equity | Prior1YearInstant | 22895000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 22982000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 500000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 553000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 500000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 553000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |